Last updated on April 17, 2014 at 10:06 EDT

Latest targretin Stories

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-02-21 08:31:07

WOODCLIFF LAKE, NJ. and MONTREAL, Quebec, Feb. 21, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE: VRX)(TSX: VRX) announced today that Valeant has acquired U.S. rights for Targretin(®) (bexarotene) capsules and Targretin(®) (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones. (Photo:...